Related Experiment Video

Updated: Aug 16, 2026

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

[Imatinib mesylate STI571 therapy for five patients with advanced gastrointestinal stromal tumors]

Kun-tang Shen1, Ying-yong Hou, Xin-yu Qin

  • 1Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai200032, China.

Zhonghua Wei Chang Wai Ke Za Zhi = Chinese Journal of Gastrointestinal Surgery
|September 13, 2005
PubMed
Abstract

Insights

STI571 (imatinib mesylate) shows therapeutic effects on advanced gastrointestinal stromal tumors (GISTs). This targeted therapy offers a promising alternative to conventional chemotherapy for unresectable or metastatic GISTs.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Gastrointestinal stromal tumors (GISTs) are a significant challenge in oncology, particularly in advanced, metastatic, or unresectable stages.
  • Conventional treatments like chemotherapy and radiofrequency ablation often show limited efficacy in advanced GISTs.
  • The c-KIT (CD117) receptor tyrosine kinase is a key driver in many GISTs.

Observation:

  • This study retrospectively analyzed 5 cases of advanced GISTs.
  • All patients had failed prior systemic chemotherapy or radiofrequency treatments and presented with extensive metastases.
  • Tumor size reduction was observed within 1-6 months of STI571 treatment.

Findings:

  • STI571 (imatinib mesylate) demonstrated significant therapeutic efficacy in advanced GISTs.
  • Treatment with STI571 led to marked tumor size reduction in all analyzed patients.
  • No serious drug-related side effects were reported during the treatment period.

Implications:

  • STI571 represents an effective chemotherapy option for advanced, unresectable, or metastatic GISTs.
  • Targeting the Kit signal-transduction pathway with STI571 offers a novel therapeutic strategy distinct from conventional chemotherapy.
  • This approach holds promise for improving outcomes in patients with advanced GISTs.

More Related Videos

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...